Study details
Enrolling now
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Memorial Sloan Kettering Cancer Center
NCT IDNCT06287528ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 4 years
Ages
17+
Locations
7 sites in NJ, NY
What this study is about
This trial is testing a new treatment called 19-28z/IL-18 CAR T cells for people with acute lymphoblastic leukemia. Participants will have their white blood cells collected and modified to become this therapy, which takes about two to four weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive 19-28z/IL-18 CAR T cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cell therapy (Engineered T-cells that target specific cancer antigens)
Endpoints
Primary: Toxicity as determined by CTCAE, version 5.0
Body systems
Oncology